Papers/PMID:30361957
Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.
World journal of urology2019The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
calciol — decreases serum prostate-specific antigen
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Compared to patients of group-A, those of group-B developed a significantly lower level of PSA at the end of treatment period (0.16 ± 0.03 ng/mL vs. 0.27 ± 0.08 ng/mL, p 0.043, OR 1.9, 95% CI 1.2-6.8).”
Quoted verbatim from Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.. - Study
- RCT
- Population
- Naive men with benign prostatic hyperplasia and moderate/severe symptoms; tamsulosin given to both arms as background, cholecalciferol added in one arm; end of 2-year treatment period
Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.2019PMID:30361957Permalink